US Brand Name(s) Belrapzo, Bendeka, Treanda
Bendamustine hydrochloride for treating the following conditions:
Indolent (slow-growing) B-cell non-Hodgkin lymphoma worsened during or after rituximab therapy.
Lymphocytic leukemia (CLL) is a kind of cancer that affects white blood cells (CLL). Bendamustine hydrochloride is also under research for cancer therapy. Bendamustine hydrochloride is a bifunctional mechlorethamine derivative having antimetabolite and alkylator properties. An alkylating group, a benzimidazole ring, which may serve as a purine analog, and a butyric acid side chain are the three active moieties in bendamustine. This drug appears to function largely as an alkylator, despite the fact that its specific mode of action is unclear.
Bendamustine metabolites alkylate and crosslink macromolecules, causing apoptosis and inhibiting DNA, RNA, and protein production. Bendamustine may be more effective than other alkylators at activating p53-dependent stress pathways and inducing apoptosis; it may also promote mitosis. It has the potential to cause mitotic catastrophe by activating a base excision DNA repair route rather than an alkyltransferase DNA repair mechanism. As a result, this agent might be more effective and resistant to drug resistance than other alkylators.
A summary of key facts regarding this medication in layman’s terms, which may contain the following:
- Cautions about this medicine
- What is the use and how?
- Whom should you consult before taking it
- What you should know about it before using it
- Other drugs that might interact with it, and possible negative effects.
Drugs are frequently under research to see whether they can assist treat or prevent conditions other than those for which they have been authorized. This patient information leaflet covers only authorized uses of the medication. Much of the material, though, might also apply to authorized uses that are being investigated.